A Single Center, Two Part, Randomized, Open Label Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Molibresib (Primary) ; Itraconazole; Rifampicin
- Indications Acute myeloid leukaemia; Breast cancer; Carcinoma; Haematological malignancies; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 20 Aug 2020 Results assessing clinical drug interaction of molibresib, published in the Journal of Clinical Pharmacology.
- 03 Mar 2017 Status changed from recruiting to completed.
- 25 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.